Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2009

Open Access 01-12-2009 | Debate

Focal therapy for prostate cancer: revolution or evolution?

Authors: Ryan Turpen, Charles J Rosser

Published in: BMC Urology | Issue 1/2009

Login to get access

Abstract

The face of prostate cancer has been dramatically changed since the late 1980s when PSA was introduced as a clinical screening tool. More men are diagnosed with small foci of cancers instead of the advanced disease evident prior to PSA screening. Treatment options for these smaller tumors consist of expectant management, radiation therapy (brachytherapy and external beam radiotherapy) and surgery (cryosurgical ablation and radical prostatectomy). In the highly select patient, cancer specific survival employing any of these treatment options is excellent, however morbidity from these interventions are significant. Thus, the idea of treating only the cancer within the prostate and sparing the non-cancerous tissue in the prostate is quite appealing, yet controversial. Moving forward if we are to embrace the focal treatment of prostate cancer we must: be able to accurately identify index lesions within the prostate, image cancers within the prostate and methodically study the litany of focal therapeutic options available.
Literature
1.
Bostwick DG, Waters DJ, Farley ER, Meiers I, Rukstalis D, Cavanaugh WA, Ragde H, Dineen MK, Bahn D, Scionti S, Babian R, Ellis DS, Rewcastle JC, Burke HB, Andriole GL, Onik G, Barqawi AE, Maksem J, Barzell WE: Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology. 2007, 70 (6 Suppl): 42-4. 10.1016/j.urology.2007.07.037.CrossRefPubMed
2.
Marberger M, Carroll PR, Zelefsky MJ, Hricak H, Scardino PT, Abenhaim LL: New Treatments for Localized Prostate Cancer. Urology. 2008, 72: 36-43. 10.1016/j.urology.2008.08.506.CrossRef
3.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J: The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008, 26 (5): 500-5.CrossRefPubMed
4.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002, 347 (16): 1233-41. 10.1056/NEJMoa022152.CrossRefPubMed
5.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002, 347 (16): 1227-32. 10.1056/NEJMoa020989.CrossRefPubMed
6.
Meiers I, Waters DJ, Bostwick DG: Preoperative Prediction of Multifocal Prostate Cancer and Application of Focal Therapy: Review 2007. Urology. 2007, 70: S3-S8I. 10.1016/j.urology.2007.06.1129.CrossRef
7.
Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ: Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat. 2007, 6 (2): 91-5.CrossRefPubMed
8.
Barzell WE, Melamed M: Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate – a 4-year experience. Urology. 2007, 70 (6 Suppl): 27-35. 10.1016/j.urology.2007.06.1126.CrossRefPubMed
9.
Onik G, Barzell : Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol. 2008, 26 (5): 506-10.CrossRefPubMed
10.
Andriole GL, Bullock TL, Belani JS, Traxel E, Yan Y, Bostwick DG, Humphrey PA: Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. Urology. 2007, 70 (6 Suppl): 22-6. 10.1016/j.urology.2007.06.1128.CrossRefPubMed
11.
Loch T: Urologic imaging for localized prostate cancer in 2007. World J Urol. 2007, 25 (2): 121-9. 10.1007/s00345-007-0155-x.CrossRefPubMed
12.
Pondman KM, Fütterer JJ, Haken B, Schultze Kool LJ, Witjes JA, Hambrock T, Macura KJ, Barentsz JO: MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol. 2008, 54 (3): 517-27. 10.1016/j.eururo.2008.06.001.CrossRefPubMed
13.
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT: Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007, 243 (1): 28-53. 10.1148/radiol.2431030580. Review. Erratum in: Radiology. 2007 Oct;245(1):302CrossRefPubMed
14.
Jager GJ, Ruijter ET, Kaa van de CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Barentsz J: Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol. 1996, 166 (4): 845-52.CrossRefPubMed
15.
Quinn SF, Franzini DA, Demlow TA, Rosencrantz DR, Kim J, Hanna RM, Szumowski J: MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology. 1994, 190 (2): 323-7.CrossRefPubMed
16.
Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS: Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005, 22 (5): 639-46. 10.1002/jmri.20431.CrossRefPubMed
17.
Haider MA, Kwast van der TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Trachtenberg J: Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007, 189 (2): 323-8. 10.2214/AJR.07.2211.CrossRefPubMed
18.
Carlani M, Mancino S, Bonanno E, Finazzi Agrò E, Simonetti G: Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. Radiol Med. 2008, 113 (5): 670-88. 10.1007/s11547-008-0271-8.CrossRefPubMed
19.
Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, Katz A, Pisters L, Rukstalis D, Shinohara K, Thrasher JB: Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008, 180 (5): 1993-2004. 10.1016/j.juro.2008.07.108.CrossRefPubMed
20.
Cohen JK, Miller RJ, Ahmed S, Lotz MJ, Baust J: Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008, 71 (3): 515-8. 10.1016/j.urology.2007.09.059.CrossRefPubMed
21.
Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M: Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002, 60 (2 Suppl 1): 3-11. 10.1016/S0090-4295(02)01678-3.CrossRefPubMed
22.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J: The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008, 26 (5): 500-5.CrossRefPubMed
23.
Prepelica KL, Okeke Z, Murphy A, Katz AE: Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005, 103: 1625-30. 10.1002/cncr.20944.CrossRefPubMed
24.
Thüroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, Desgrandchamps F, De La Rosette JJ, Gelet A: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol. 2003, 17 (8): 673-7. 10.1089/089277903322518699.CrossRefPubMed
25.
Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B: Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology. 2008, 72 (6): 1329-33. 10.1016/j.urology.2008.06.062. discussion 1333-4CrossRefPubMed
26.
Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S: Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008, 38 (3): 192-9. 10.1093/jjco/hym173.CrossRefPubMed
27.
Huang Z, Chen Q, Dole KC, Barqawi AB, Chen YK, Blanc D, Wilson BC, Hetzel FW: The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues – in vivo study in a canine model. Photochem Photobiol Sci. 2007, 6 (12): 1318-24. 10.1039/b705984a.CrossRefPubMedPubMedCentral
28.
Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, Evans A, Scherz A, Savard J, Chin JL, Wilson BC, Elhilali M: Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008, 102 (5): 556-62. 10.1111/j.1464-410X.2008.07753.x.CrossRefPubMed
29.
Emberton M: VTP for Men with Prostate Cancer – Early Results. J Endourology. 2008, 22: 03-
30.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
31.
Iczkowski KA, Hossain D, Torkko KC, Qian J, Lucia MS, Wheeler TM, Rewcastle JC, Bostwick DG: Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology. 2008, 71 (6): 1166-71. 10.1016/j.urology.2007.10.013.CrossRefPubMed
32.
Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT: Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy. Urology. 2008, 72: 12-24. 10.1016/j.urology.2008.10.004.CrossRef
33.
Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L, International Task Force on Prostate Cancer and the Focal Lesion Paradigm: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007, 178 (6): 2260-7. 10.1016/j.juro.2007.08.072.CrossRefPubMed
Metadata
Title
Focal therapy for prostate cancer: revolution or evolution?
Authors
Ryan Turpen
Charles J Rosser
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2009
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-9-2

Other articles of this Issue 1/2009

BMC Urology 1/2009 Go to the issue

Research article

Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience

Research article

Identifying the needs of penile cancer sufferers: A systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer

Research article

A systematic review of the diagnostic accuracy of prostate specific antigen

Research article

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma

Commentary

Does the biomarker search paradigm need re-booting?

Research article

Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis